Brillian Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRILLIAN PHARMA
BRILLIAN PHARMA has one approved drug.
Drugs and US Patents for Brillian Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brillian Pharma | SDAMLO | amlodipine besylate | FOR SOLUTION;ORAL | 219531-002 | Jul 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Brillian Pharma | SDAMLO | amlodipine besylate | FOR SOLUTION;ORAL | 219531-003 | Jul 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Brillian Pharma | SDAMLO | amlodipine besylate | FOR SOLUTION;ORAL | 219531-001 | Jul 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

